SEMA4D and juvenile Huntington disease: The inhibition of SEMA4D/PlexinB1 signaling has been found to show clear therapeutic effects in multiple types of tumors (Evans et al, 2015), rheumatoid arthritis (Yoshida et al, 2015), multiple sclerosis (Smith et al, 2014), Huntington's disease (Southwell et al, 2015), and stroke (Zhou et al, 2018b) in preclinical studies.